41st Annual J.P. Morgan Healthcare Conference
Biosimilar mAbs market opportunities expanding
Global Biosimilar Market Outlook¹
$20B
Approved
biosimilars²
$30B
2022
2025
97 programs in development²
8 years after
1st biosimilar approval
15
$60B
36
2030
21
launched
23
mAbs
EU
US
¹ McKinsey & Co, An inflection point for biosimilars, June 2021.
² Amgen Biosimilars 2022 Trend Report. 1st approvals: 2006 EU, 2015 US
R REPLIGEN
"Top 6" mAbs with launched biosimilars
US FDA
approved
biosimilars
81
JH
HUMIRA
adalimumab
LUCENTIS
RANIBIZUMAB INJECTION
X
AVASTIN
bevacizumab
MALINJECTION FOR
Remicade
INFLIXIMAB
Herceptin
trastuzumab
21 mg/mL INJECTION FOR INTRAVENOUS USE
Rituxan
Rituximab
Total Sales
2021
Sales
$20.7B
$3.6B
$3.4B
$3.2B
$2.9B
$2.8B
$36.6B
¹2 additional approvals pending for 1H-23
2
1
3
4
LO
5
3
24 approved
14 launched
Looking Ahead:
8 Humira biosimilars
go commercial in
2023
4 additional
blockbuster mAbs²
with $29B in
2021 sales come
off patent over the
next 5 years
Opdivo (BMS), Perjeta® (Roche), Stelara® (Janssen), Eylea® (Regeneron)
9View entire presentation